Molecular Adjuvant Effects of a Conformationally Biased Agonist of Human C5a Anaphylatoxin

Journal of Immunology

Volumn 158, Issue 3, 1997, Pages 1377-1382

  Tempero, Richard M ^a   Hollingsworth, Michael A ^a   Burdick, Michael D ^a   Finch, Angela M ^b   Taylor, Stephen M ^b   Vogen, Shawn M ^a   Morgan, Edward L ^c   Sanderson, Sam D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; CA 15-3 ANTIGEN; COMPLEMENT COMPONENT C5A; IMMUNOLOGICAL ADJUVANT; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; DRUG POTENTIATION; EPITOPE MAPPING; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; MOLECULAR GENETICS; MOUSE; PROTEIN CONFORMATION; RABBIT;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANAPHYLATOXINS; ANIMALS; CA-15-3 ANTIGEN; COMPLEMENT C5A; EPITOPE MAPPING; HUMANS; IMMUNOLOGIC TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN CONFORMATION; RABBITS; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 0031065195     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Pepys, M. B. 1976. The role of complement in the induction of immune response. Transplant. Rev. 32:93.
2. Hugli, T. E., and E. L. Morgan. 1984. Mechanisms of leukocyte regulation by complement derived factors. Contemp. Top. Immunobiol. 14:109.
3. Morgan, E. L. 1986. Modulation of the immune response by anaphylatoxins. Complement 3:128.
4. Jacquier-Sarlin, M. R., F. M. Gabert, M.-B. Villiers, and M. G. Colomb. 1995. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 84:164.
5. Dempsey, P. W., M. E. D. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348.
6. Morgan, E. L. 1993. Complement fragment C5a and immunoregulation. In Complement Today. Vol. 1: Complement Profiles. J. M. Cruse and R. E. Lewis, Jr., eds. Karger, Basel, p. 56.
7. Goodman, M. G., D. E. Chenoweth, and W. O. Weigle. 1982. Potentiation of the primary humoral immune response in vitro by C5a anaphylatoxin. J. Immunol. 129:70.
8. Morgan, E. L., M. L. Thoman, W. O. Weigle, and T. E. Hugli. 1983. Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune response. J. Immunol. 130:1257.
9. Montz, H., A. Fuhrmann, M. Schulze, and O. Gotze. 1990. Regulation of human autologous T cell proliferation by endogenously generated C5a. Cell. Immunol. 127:337.
10. Hogan, M. M., K. B. Yancy, and S. N, Vogel. 1989. The role of C5a in the induction of tumoricidal activity in C3H/HeJ (Lspd) and C3H/OuJ (Lspn) macrophages. J. Leukocyte Biol. 46:565.
11. Okusawa, S., C. A. Dinarello, K. B. Yancy, S. Endres, T. J. Lawley, M. M. Frank, J. F. Burke, and J. A. Gelfand. 1987. C5a induction of interleukin-I synergistic effect with endotoxin or interferon gamma. J. Immunol. 139:2656.
12. Cavaillon, J. M., C. Fitting, and N. Haeffner-Cavaillon. 1990. Recombinant C5a enhances interleukin-1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur. J. Immunol. 20:253.
13. Schindler, R., J. A. Gelfand, and C. A. Dinarello. 1990. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translation signal provided by lipopolysaccharide and IL-1 itself. Blood 76:1631.
14. Scholz, W., M. R. McClurg, G. J. Cardenas, M. Smith, D. J. Noonan, T. E. Hugli, and E. L. Morgan. 1990. C5a-mediated release of interleukin-6 by human monocytes. Clin. Immunol. Immunopathol. 57:297.
15. Morgan, E. L., S. D. Sanderson, W. Scholz, D. J. Noonan, W. O. Weigle, and T. E. Hugli. 1992. Identification and characterization of the effector region within human C5a responsible for stimulation of 1L-6 synthesis. J. Immunol. 148:3937.
16. Ember, J. A., S. D. Sanderson, T. E. Hugli, and E. L. Morgan. 1994. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am. J. Pathol 144:393.
17. Wetsel, R. A. 1995. Structure, function, and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 7:48.
18. Sozzani, S., F. Sallusto, W. Luini, D. Zhou, L. Piemonti, P. Allavena, J. VanDamme, S. Valitutti, A. Lanzavecchia, and A. Mantovani. 1996. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J. Immunol. 155:3292.
19. Van Epps, D. E., S. Simpson, J. G. Bender, and D. E. Chenoweth. 1990. Regulation of C5a and formyl peptide receptor expression on human polymorphonuclear leukocytes. J. Immunol. 144:1062.
20. Hugli, T. E., and J. Muller-Eberhard. 1978. Anaphylatoxins C3a and C5a. Adv. Immunol. 26:1.
21. Hugli, T. E. 1981. The structural basis for anaphylatoxins and chemotactic functions of C3a and C5a. Crit. Rev. Immunol. 114:321.
22. Mollison, K. W., W. Mandecki, E. R. P. Zuiderweg, L. Fayer, T. A. Fey, R. A. Krause, R. G. Conway, L. Miller, R. P. Edalji, M. A. Shallcross, B. Lane, J. L. Fox, J. Greer, and G. W. Carter. 1989. Identification of receptor binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA 86:292.
23. Zuiderweg, E. R. P., D. G. Nettesheim, K. W. Mollison, and G. W. Carter. 1989. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry 28:172.
24. Ember, J. A., S. D. Sanderson, S. M. Taylor, M. Kawahara, and T. E. Hugli. 1992. Biologic activity of synthetic analogues of C5a Anaphylatoxin. J. Immunol. 148: 3165.
25. Sanderson, S. D., L. Kirnarsky, S. A. Sherman, J. A. Ember, A. M. Finch, and S. M. Taylor. 1994. Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory activities. J. Med. Chem. 37:3171.
26. Sanderson, S. D., L. Kirnarsky, S. A. Sherman, S. M. Vogen, O. Prakash, J. A. Ember, A. M. Finch, and S. M. Taylor. 1995. Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response. J. Med. Chem. 38:3669.
27. Kawatsu, R., S. D. Sanderson, I. Blanco, N. Kendall, A. M. Finch, S. M. Taylor, and D. Colcher. 1996. Conformationally biased analogs of human C5a mediate changes in vascular permeability. J. Pharmacol. Exp. Ther. 278:432.
28. Rollins, T. E., and M. S. Springer. 1985. Identification of the polymorphonuclear leukocyte c5a receptor. J. Biol. Chem. 260:7157.
29. Morgan, E. L., J. A. Ember, S. D. Sanderson, W. Scholz, R. Buchner, R. D. Ye, and T. E. Hugli. 1993. Anti-C5a receptor antibodies: characterization of neutralizing antibodies specific for a peptide. C5aR(9-29), derived from the predicted amino-terminal sequence of human C5a receptor. J. Immunol. 151:377.
30. Batra, S. K., H. F. Kern, A. J. Worlock, R. S. Metzgar, and M. A. Hollingsworth. 1991. Transfection of the human Muc1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc-1: integration, expression and ultrastructural changes. J. Cell. Sci. 100:841.
31. Morgan, E. L., S. D. Sanderson, W. Scholz, D. J. Noonan, M. V. Hobbs, W. O. Weigle, and T. E. Hugli. 1992. Regulation of human immune function by human C5a and analogue peptides. FASEB J. 6:1121.